Mission Wealth Management
CRVS icon

Mission Wealth Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Mission Wealth Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-40,000
Closed -$211K – 677
2024
Q3 		$211K Buy
+40,000
New +$144K 0.01% 628

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Samlyn Capital
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Mission Wealth Management's CRVS Position: Q4 2024 in Review

Mission Wealth Management sold out of Corvus Pharmaceuticals (CRVS) in Q4 2024, closing a stake of 40,000 shares — an estimated $211K sold.

Mission Wealth Management first reported a position in CRVS in Q3 2024 and held it in 1 quarter. The position peaked at $211K in Q3 2024. 85 funds tracked by Wall St. Rank hold CRVS as of Q4 2024.

  • Mission Wealth Management reported no remaining Corvus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Mission Wealth Management sold 40,000 Corvus Pharmaceuticals shares in Q4 2024, an estimated $211K.
  • Mission Wealth Management first reported a position in Corvus Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Mission Wealth Management's Corvus Pharmaceuticals position peaked at $211K in Q3 2024.
  • 85 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2024.

Based on Mission Wealth Management's 13F filing for Q4 2024, filed 6 Feb 2025.